FASLG and metabolic dysfunction-associated steatotic liver disease: For example, it would be wise to measure established biomarkers of apoptosis (e.g. caspase-cleaved cytokeratin 18) concurrently with sFasL so that correlations between the two can be calculated; a positive correlation would underscore the role of sFasL as a biomarker of apoptosis in the context of NAFLD.